1-3 of 3
Geoffrey T. Yarranton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors

Chin Pan, Pina M. Cardarelli, Matthew H. Nieder, Lesley B. Pickford, Sanjeev Gangwar, David J. King, Geoffrey T. Yarranton, Dana Buckman, William Roscoe, Fengmin Zhou, Adam Salles, Tseng-Hui Chen, Killian Horgan, Yi-Hong Wang, Thi Nguyen, Christopher R. Bebbington
Journal: Cancer Research
Cancer Res (2003) 63 (17): 5526–5531.
Published: 18 September 2003
View article titled, CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10<sup>+</sup> Tumors
Open the PDF for CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10<sup>+</sup> Tumors in another window
Journal Articles

CPI-0004Na, a New Extracellularly Tumor-Activated Prodrug of Doxorubicin: In Vivo Toxicity, Activity, and Tissue Distribution Confirm Tumor Cell Selectivity

Vincent Dubois, Luc Dasnois, Karim Lebtahi, Françoise Collot, Nathalie Heylen, Nathalie Havaux, Anne-Marie Fernandez, Thomas J. Lobl, Cecilia Oliyai, Matthew Nieder, Dan Shochat, Geoffrey T. Yarranton, André Trouet
Journal: Cancer Research
Cancer Res (2002) 62 (8): 2327–2331.
Published: 01 April 2002
View article titled, CPI-0004Na, a New Extracellularly Tumor-Activated Prodrug of Doxorubicin: <subtitle> <em>In Vivo</em> Toxicity, Activity, and Tissue Distribution Confirm Tumor Cell Selectivity</subtitle>
Open the PDF for CPI-0004Na, a New Extracellularly Tumor-Activated Prodrug of Doxorubicin: <subtitle> <em>In Vivo</em> Toxicity, Activity, and Tissue Distribution Confirm Tumor Cell Selectivity</subtitle> in another window
Journal Articles

Improved Tumor Targeting with Chemically Cross-Linked Recombinant Antibody Fragments

David J. King, Alison Turner, Andrew P. H. Farnsworth, John R. Adair, Raymond J. Owens, R. Barbara Pedley, Darren Baldock, Karen A. Proudfoot, Alastair D. G. Lawson, Nigel R. A. Beeley, Kenny Millar, T. Andrew Millican, Byron A. Boyce, Pari Antoniw, Andrew Mountain, Richard H. J. Begent, Dan Shochat, Geoffrey T. Yarranton
Journal: Cancer Research
Cancer Res (1994) 54 (23): 6176–6185.
Published: 01 December 1994
View article titled, Improved Tumor Targeting with Chemically Cross-Linked Recombinant Antibody Fragments
Open the PDF for Improved Tumor Targeting with Chemically Cross-Linked Recombinant Antibody Fragments in another window